Metadata
- Name
- ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04732065
- Description
- This phase I trial studies the effects and best dose of ONC206 alone or in combination with
radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed
or has come back (recurrent) or other recurrent primary malignant brain tumors. ONC206 is a
recently discovered compound that may stop cancer cells from growing. This drug has been
shown in laboratory experiments to kill brain tumor cells by causing a so called "stress
response" in tumor cells. This stress response causes cancer cells to die, but without
affecting normal cells. ONC206 alone or in combination with radiation therapy may be
effective in treating newly diagnosed or recurrent diffuse midline gliomas and other
recurrent primary malignant brain tumors. - Data or Study Types
- clinical trial
- Keywords
- H3 K27M-Mutant, Brain Tumors
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2021
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04732065
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04732065